VRAX
Virax Biolabs Group Limited Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.11M
P/E Ratio
—
EPS
$-1.31
Beta
1.60
52W High
$1.34
52W Low
$0.13
50-Day MA
$0.21
200-Day MA
$0.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 2,986 |
| Gross Profit (TTM) | -45,306 |
| EBITDA | $-5.56M |
| Operating Margin | -160788.00% |
| Return on Equity | -83.80% |
| Return on Assets | -48.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.81 |
| Price-to-Book | 0.24 |
| Price-to-Sales (TTM) | 372.91 |
| EV/Revenue | 66.65 |
| EV/EBITDA | 0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.50% |
| Shares Outstanding | $7.42M |
| Float | $5.50M |
| % Insiders | 4.00% |
| % Institutions | 9.61% |
Data last updated: 4/9/2026